Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous cord blood stem cells + autologous platelet-rich plasma
- Development stage
- Unknown
- Lead developer
- Shenyang Maternal and Child Care Service Center
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Subcutaneous
01
Overview
Autologous cord blood stem cells + autologous platelet-rich plasma is an investigational, cell-based biologic combination therapy being developed by the Shenyang Maternal and Child Care Service Center for the treatment of striae gravidarum (pregnancy-related stretch marks). The therapy consists of two autologous components derived from the patient's own cord blood at delivery: cord blood stem cells (hematopoietic and/or mesenchymal) and platelet-rich plasma (PRP), which is a concentrate of platelets and growth factors. Administered via subcutaneous injection into the affected abdominal skin, the therapy aims to improve the appearance of stretch marks through stem cell-mediated tissue regeneration and the action of PRP-derived growth factors—such as PDGF, TGF-β, EGF, FGF, and VEGF—which stimulate collagen synthesis, fibroblast proliferation, and skin remodeling.
- Other names
- autologous cord blood stem cell plus platelet-rich plasmaCBSC + PRPautologous cord blood stem cells and platelet-rich plasma
Beyond the preview
Go deeper on autologous cord blood stem cells + autologous platelet-rich plasma.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous cord blood stem cells + autologous platelet-rich plasma.